Absci Corporation: Struggling To Live Up To Its AI Promise
Summary: Absci Corporation's stock has rebounded due to new collaborations, but skepticism about AI's impact on drug...
Tag: ABSI
Absci: Embryonic Pipeline Looks Expensive Relative To Peers
Summary: Absci's differentiated drug discovery platform could create significant shareholder value long term.The company...
Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
Summary: Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected...
Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships
Summary: Absci Corporation uses IDCP technology to quickly produce high-quality drug candidates in as little as six weeks,...
Absci: ‘AI’ Tag Keeping Company Afloat While Searching For Right Formula
Summary: Absci Corporation, an AI-driven drug discovery company, has seen its share price plummet after its IPO in July...
Absci: Differentiated Antibody Discovery Play
Summary: Absci combines generative AI with scalable wet lab technologies to improve antibody discovery, with the eventual...
Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out
Summary: Absci, a Vancouver-based drug discovery company that IPOd in July last year, has seen its market cap fall from...
IPO Day With Absci CEO Sean McClain – The Google Of Synthetic Biology (Video)
Summary: Absci, a synthetic biology company whose platform technology aids in the drug discovery process, is going public...
AbSci Proposes Terms For $200 Million IPO
Summary: AbSci has filed to raise $200 million in a U.S. IPO.The firm is commercializing a biologic development...